Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge

Bristol Myers Squibb raised its full-year revenue forecast on ‌Thursday, citing strong sales of its newer medicines, but lowered its 2026 earnings per share projection due to a hefty acquisition-related charge.

Reuters • 13 hours ago

Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers Squibb's Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion. Adjusted EPS fell 17% to $1.35, but mostly because of deal accounting, not a weaker core business.

The Motley Fool • 5 hours ago

The Big Caveat Behind Bristol Myers' Sales Guidance Boost

Bristol Myers Squibb stock rose Thursday despite a "mixed bag" performance that included a miss from its biggest cancer drug.

Investors Business Daily • 11 hours ago

Bristol Myers Squibb Raises Outlook as Quarterly Revenue Rises

Bristol Myers Squibb raised its full-year revenue outlook due to higher third-quarter revenue.

WSJ • 13 hours ago

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2026.

Business Wire • 13 hours ago

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.

Zacks Investment Research • 7 hours ago

Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript

Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript

Seeking Alpha • 7 hours ago

Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.63 per share a year ago.

Zacks Investment Research • 10 hours ago

Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings

The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • 9 hours ago

Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It Matters

It also demonstrated very promising results when evaluated in other solid tumors. The company's involvement in the program is part of a broader effort to develop its burgeoning growth portfolio.

The Motley Fool • Oct 27, 2026